AI assistant
Sending…
Processa Pharmaceuticals, Inc. — Director's Dealing 2022
Apr 20, 2022
35172_dirs_2022-04-19_d276b819-0b5d-4dce-8c0c-f6e5bbc1c32d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Processa Pharmaceuticals, Inc. (PCSA)
CIK: 0001533743
Period of Report: 2022-03-15
Reporting Person: Yorke Justin W (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-01-01 | Restricted Stock | $0 | A | 18208 | Acquired | Common Stock (18208) | Direct |
Footnotes
F1: Restricted stock units vest 100% on December 31, 2022.
More from Processa Pharmaceuticals, Inc.
Regulatory Filings
2026
Feb 19
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 7
Regulatory Filings
2025
Dec 15
Major Shareholding Notification
2025
Nov 7
Interim / Quarterly Report
2025
Nov 6
Major Shareholding Notification
2025
Oct 15